This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): Alteplase, Actilyse, Catheter Tissue Plasminogen Activator
Description: Cathflo Activase is alteplase, a recombinant thrombolytic, indicated for the restoration of function to central venous access devices - catheters and other indwelling ports - as assessed by a restored ability to withdraw blood after clot (thrombus) dissolution.
Revenue for Cathflo Activase is included in the Activase revenue model.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Genentech has licensed rights for Cathflo Activase for a number of countries outside the U.S., Canada, and Japan to Boehringer Ingelheim.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Boehringer Ingelheim GmbH
Cathflo Activase News
Pink Sheet Genentech Cathflo Activase is approved
Additional information available to subscribers only: